Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | RCC data at ESMO 2020

Laurence Albiges • 18 Sep 2020
ESMO 2020
Genitourinary Cancer Kidney Cancer Cabozantinib Nivolumab Sunitinib
CheckMate 9ER

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, highlights the important studies being reported at the ESMO 2020 virtual meeting. Dr Albiges highlights the CheckMate 9ER clinical trial (NCT03141177) as one to look out for. This phase III study compared nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma (RCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Laurence Albiges

2:48
LITESPARK-005: Belzutifan versus everolimus in ccRCC
Laurence Albiges • 21 Oct 2023
4:21
Biomarker development in RCC and UC
Laurence Albiges • 23 Sep 2021
2:24
Current and emerging treatment strategies for patients with mccRCC
Laurence Albiges • 23 Sep 2021
1:50
BIONIKK: the first trial study in mccRCC
Laurence Albiges • 18 Sep 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals